Comparison of the efficacy and safety of fenofibrate and lovastatin in patients with primary type IIa or IIb hyperlipidaemia

Journal of Clinical Pharmacy and Therapeutics

Volumn 23, Issue 3, 1998, Pages 213-221

  Gholami, K ^a   Tavakoli, N ^a   Maleki, M ^a   Shafiee, A ^a,b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; FENOFIBRATE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; TRIACYLGLYCEROL;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MYALGIA; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; CHOLESTEROL; FEMALE; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LOVASTATIN; MALE; MIDDLE AGED; PROCETOFEN; TIME FACTORS; TRIGLYCERIDES;

EID: 0031726644     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.1998.00154.x     Document Type: Article

References (31)

1. Kannel WB, Doyle JT, Ostfeld AM, et al. (1984) Atherosclerosis study group. Optimal resources for primary prevention of atherosclerotic diseases. Circulation, 70, 155-205A.
2. Pyorala K, De Backer C, Graham I, Poole-Wilson P, Wood D. (1994) Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Atherosclerosis, 110, 121-161.
3. Grundy SM. (1997) Cholesterol and coronary heart disease: the 21st century. Archives of Internal Medicine, 157, 1177-1184.
4. LaRosa JC. (1997) Triglycerides and cononary risk in women and the elderly. Archives of Internal Medicine, 157, 961-968.
5. Patsch JR. (1994) Triglyceride-rich lipoproteins and atherosclerosis. Atherosclerosis, 110, S23-S26.
6. Austin MA. (1991) Plasma triglyceride and coronary heart disease. Arteriosclerosis and Thrombosis, 11, 2-14.
7. Peto R, Yusuf S, Collins R. (1985) Cholesterol lowering trial results in their epidemiological co. Circulation, 72, 451 (Abstract no. 1083).
8. National Cholesterol Education Program. (1994) Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation, 89, 1329-1445.
9. Hahmann HW, Bunte T, Hellwig N, et al. (1991) Progression and regression of minor coronary arterial narrowings by quantitative angiography after fenofibrate therapy. American Journal of Cardiology, 67, 957-961.
10. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. (1987) Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. Journal of the American Medical Association, 257, 3233-3240.
11. Witztum JL. (1996) Drugs used in the treatment of hyperlipoproteinemias. In: The Pharmacological Basis of Therapeutics, eds Hardman JG, Limbird LE, Molinotf PB, Ruddon RW, Goodman Gilman A, 9th edn, pp. 875-897, McGrow-Hill Co. Inc., New York.
12. O'Connor P, Feely J, Shepherd J. (1990) Lipid lowering drugs. British Medical Journal, 300, 667-672.
13. Schonfeld G. (1991) Drug treatment of hyperlipoproteinemias. In: Primary Hyperlipoproteinemias. eds Steiner G, Shefrir E, pp. 321-335, McGrow-Hill Co. Inc., New York.
14. Henwood JM, Heel RC. (1988) Lovastatin: a preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidemia. Drugs, 36, 429-454.
15. Lovastatin 5-Year Safety and Efficacy (1993) Lovastatin Study Groups I through IV. Archives of Internal Medicine, 153, 1079-1087.
16. Schonfeld G. (1994) The effects of fibrates on lipoprotein and hemostatic coronary risk factors. Atherosclerosis, 111, 161-174.
17. Balfour JA, McTavish D, Heel RC. (1990) Fenofibrate: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs, 40, 260-290.
18. Brown WV, Dujovne CA, Farquhar JW, et al. (1986) Effects of fenofibrate on plasma lipids: double-blind, multicenter study in patients with type IIa or IIb hyperlipidemia. Arteriosclerosis, 6, 670-678.
19. Blane CF. (1989) Review of European clinical experience with fenofibrate. Cardiology, 76, 1-13.
20. Burstein M, Scholnick HR, Morfin R. (1970) Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. Journal of Lipid Research, 11, 583-595.
21. Lopes-Virella MF, Stone P, Ellis S, Colwell JA. (1977) Cholesterol determination in high density lipoproteins separated by three different methods. Clinical Chemistry, 23, 882-884.
22. Friedewald WT, Levy RI, Fredrickson DS. (1972) Estimation of the concentration of low density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clinical Chemistry, 18, 499-502.
23. Clauss A. (1957) Rapid physiological coagulation method in determination of fibrinogen. Acta Haematology, 17, 237-240.
24. Bradford RH, Shear CL, Chremos AN, et al. (1991) Expanded clinical evaluation of lovastatin (EXCEL) study results, 1: efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Archives of Internal Medicine, 151, 43-49.
25. Illingroworth DR. (1991) Clinical implications of new drugs for lowering plasma cholesterol concentrations. Drugs, 41, 151-160.
26. Caslake MJ, Packard CJ, Gaw A, et al. (1993) Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia. Arteriosclerosis and Thrombosis, 13, 702-711.
27. Sinzinger H, Pirich C, Kondor P, Etti H. (1995) Atherogenic risk reduction in patients with dyslipidaemia. comparison between bezafibrate and lovastatin. European Heart Journal, 16, 1491-1501.
28. Sommariva D, Bontiglioli D, Pogliaghi I, Ottomano C, Fasoli A. (1984) Fenofibrate therapy of hypertriglyceridaemias. Differential effects on LDL cholesterol level in type IV and in type IIb primary hyperlipoproteinaemia. European Journal of Clinical Pharmacology, 26, 741-744.
29. Ernst E. (1990) Plasma fibrinogen: an independent cardiovascular risk factor. Journal of Internal Medicine, 227, 365-372.
30. Kannel WB, D'Agostino RB, Belanger AJ. (1987) Fibrinogen, cigarette smoking and risk of cardiovascular disease: insights from the Framingham study. American Heart Journal, 113, 1006-1010.
31. Branchi A, Rovellini A, Sommariva D, Gugliandolo AG, Fasoli A. (1993) Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia. Thrombosis and Haemostasis, 70, 241-243.